Group of Takeda’s shareholders opposes $62bn acquisition of Shire

Kazu Takedahas, founder of Takeda Pharmaceutical, is opposing the acquisition of Shire and, together with a group of small investors, is trying to block the transaction which, in his opinion, would result in a disaster for the company.

The group of opponents includes  Kazu Takedahas and representatives of 130 families, who have named themselves “Thinking about Takeda’s Bright Future” (TTBF). TTBF shareholders–who account as a minority in the total number of shareholders–are convinced that the acquisition will cause a loss of corporate identity and that the $62bn paid–that is GBP49 per share, or 64% premium–has been too high.

(Source: The Sunday Times)